U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer
SAN DIEGO, July 8, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADRX-0405, for the treatment of patients with gastric cancer.
ADRX-0405 is a STEAP1 ADC being evaluated in the Phase 1a portion of an ongoing Phase 1a/b clinical trial (NCT06710379) for the treatment of select advanced solid tumors, including metastatic castration resistant prostate cancer, gastric cancer, and non-small cell lung cancer. While STEAP1 is primarily associated with prostate cancer, there is a meaningful amount of target expression in gastric cancer, making this a potential indication of interest for future clinical development.
"Receiving orphan drug designation from FDA is a notable milestone for Adcentrx and reinforces the potential for ADRX-0405 to improve the lives of patients with gastric cancer," said Hui Li, Ph.D., Founder and Chief Executive Officer of Adcentrx. "We are encouraged by the progress of our Phase 1a trial and look forward to further evaluating the safety, tolerability and anti-tumor activity of ADRX-0405 in gastric and other cancers."
Gastric cancer, or stomach cancer, is a serious malignancy that develops in the stomach lining and is often diagnosed at advanced stages. The American Cancer Society estimates there will be 30,300 new cases of gastric cancer in the U.S. in 2025, meeting FDA's criteria for a rare disease. The orphan drug designation is a program designed to stimulate the development of treatments for rare diseases, defined as conditions affecting fewer than 200,000 people in the U.S. Benefits of this designation include access to grant funding and scientific assistance, tax credits for qualified clinical trials, waiver of Prescription Drug User Fee Act (PDUFA) application fees, and the potential for seven years of market exclusivity following regulatory approval.
About ADRX-0405ADRX-0405 is a clinical-stage next-generation ADC targeting six-transmembrane epithelial antigen of the prostate 1 (STEAP1), a cell surface protein that is upregulated in prostate cancer and certain other cancers with limited expression in normal healthy tissue. The ADC is composed of a humanized IgG1 antibody coupled with a novel topoisomerase inhibitor linker-payload through Adcentrx's innovative i-Conjugation® technology platform – a core component in the design of the company's ADCs. The platform utilizes a cleavable linker and stable conjugation chemistry to enhance payload delivery. This novel technology enables a highly stable ADC with a drug-antibody ratio of eight (DAR 8) to maximize payload delivery to solid tumors. ADRX-0405 preclinical studies have demonstrated its favorable pharmacokinetics, safety profile, and significant efficacy across multiple animal tumor models. ADRX-0405 is currently being evaluated in a Phase 1a/b clinical trial.
For more information about the ADRX-0405 Phase 1a/b clinical trial, please refer to the Study ID NCT06710379 on ClinicalTrials.gov.
About Adcentrx TherapeuticsAdcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. Adcentrx has pioneered the development of an ADC technology platform addressing key components of protein conjugate design to solve challenges typically seen in ADCs. Adcentrx is developing a robust pipeline including two clinical-stage ADCs and multiple preclinical ADCs, all with first-in-class and best-in-class potential.
For more information about Adcentrx and its innovative ADC technologies, please visit https://adcentrx.com.
Contact Information:Investor Relationsir@adcentrx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/us-fda-grants-orphan-drug-designation-to-adcentrx-therapeutics-adrx0405-steap1-adc-for-gastric-cancer-302499372.html
SOURCE Adcentrx Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Jeeva.ai Launches Jeeva 2.0, Empowering GTM Teams with Agentic AI for 10x Sales Productivity
SAN FRANCISCO, July 21, 2025--(BUSINESS WIRE)-- a cutting-edge AI-driven sales automation platform, today announced the launch of Jeeva 2.0, marking a major milestone as it opens its powerful autonomous sales assistant capabilities to every member of the go-to-market (GTM) team. This Product-Led Growth (PLG) launch on Product Hunt aims to revolutionize how sales professionals operate by delivering AI-powered tools designed to amplify productivity, precision, and personalization. Dubbed the "Cursor/Codex for sales reps," Jeeva 2.0 blends advanced AI with deep sales expertise to automate repetitive and time-consuming tasks, giving reps more time to focus on high-impact conversations and closing deals. Key new features include: Auto Email Drafting & Inbox Labeling: Personalization at ScaleJeeva 2.0 streamlines email outreach by auto-drafting personalized messages based on past interactions and customer data, saving reps hours weekly while preserving their authentic voice. Its inbox labeling feature organizes incoming emails automatically, helping reps prioritize and respond efficiently. Automated Meeting Notes: Stay PresentAutomatic note-taking captures key points in real time, letting reps focus fully on conversations without missing important details. AI-Powered Calendar: Simplify SchedulingThe AI calendar helps coordinate meetings, optimize schedules, and prevent conflicts—making time management effortless. Meeting Preparation Assistance: Arrive ReadyBefore meetings, Jeeva 2.0 surfaces relevant insights about prospects and past interactions so reps can engage confidently. "Jeeva 2.0 is designed to empower every GTM team member, not just sales leaders, to become 10x more productive and effective," said Gaurav Bhattacharya, CEO of "By automating the grunt work and enabling truly personalized outreach and research at scale, we help teams unlock pipeline growth and revenue acceleration like never before." The launch on Product Hunt on July 21 will feature live demos, user stories, and a showcase of Jeeva's new autonomous AI assistants. invites GTM professionals worldwide to experience the future of sales automation and join the growing community transforming sales with AI. About Jeeva Jeeva is an agentic AI sales platform that automates prospect discovery, data enrichment, personalized outreach, and post-call follow-up in a single workflow. Drawing on live intent signals and self-directed processes, it surfaces high-fit leads, fills data gaps with accurate firmographic and contact information, drafts context-aware emails, and captures meeting notes—allowing sales teams to concentrate on relationships and revenue. Companies from seed-stage startups to large enterprises rely on Jeeva to expand pipeline and shorten sales cycles without adding headcount. Founded by serial entrepreneur Gaurav Bhattacharya, Jeeva operates globally. View source version on Contacts Address: 2708 Wilshire Blvd, #321, Santa Monica, CA 90403Gaurav Bhattacharya, CEO, Email - g@ Phone - 4246457525 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
11 minutes ago
- Medscape
Breast Growth: Cancer or Coincidence in 42-Year-Old?
A 42-year-old woman presented with an atypical enlarging breast mass over the course, which initially raised suspicion of a serious condition but resolved spontaneously. Initial physical examination revealed skin ulcerations and nipple retraction, raising suspicion for inflammatory breast cancer. Biopsy revealed acute and chronic inflammation, granulation-type tissue, and focal granuloma with suppuration, but no evidence of malignancy. With the diagnosis still unclear, the patient was asked to return within 1 month. However, upon her return, the breast mass and positive axillary lymph node had decreased in size significantly, with ulcerated areas showing signs of healing. The case reported by Junisha Martin, a medical student at Ross University School of Medicine in Miami, highlighted the importance of considering a wide range of potential diagnoses. The Patient and Her History The patient with no significant past medical history presented with an enlarging 4.5 cm mass over 2.5 months in the right breast. The patient disclosed that 2 years ago, she had experienced a lemon-sized lump in her right breast that had persisted for approximately 2 months. The mass was accompanied by small superficial ulcerations on the overlying skin and occasional discomfort. The mass completely resolved during that time, and no medical treatment was sought. Six months later, the mass returned to the same location and increased in size, with ulcerations in the areolar region. The patient declined to undergo mammography during that time because of the discomfort of the areolar lesion. The past surgical history consisted of three prior caesarean sections. The patient denied any allergies, smoking, recent travel, pets at home, or use of topical creams and ointments on the affected area. The patient denied any significant family or social history. Findings and Diagnosis On admission, patient vitals were obtained and reported normal: temperature 36.8 °C, blood pressure 132/88 mm Hg, heart rate 84 beats/min, respiratory rate 19 breaths/min, and oxygen saturation 99% on room air. She was alert and in no acute distress on physical examination. Physical examination revealed that the large right breast mass had decreased in size significantly. The mass now measured 3 cm from 4.5 cm and was non-tender, with minimal nipple retraction and healing ulcerations and scars with improving skin discoloration. The patient was scheduled for an ultrasound-guided core biopsy of the right breast and right axillary lymph node due to a high suspicion of malignancy, instead of fine-needle aspiration cytology. A core biopsy of the right breast at 12:00 revealed acute and chronic inflammation, granulation-type tissue, and focal granuloma with suppuration. Immunohistochemical tests were negative for carcinoma. A right axillary lymph node biopsy revealed sinus histiocytosis and acute non-specific lymphadenitis but no evidence of malignancy. During the follow-up visit after 1 week, the patient reported feeling well, with mild soreness at the biopsy site. Repeated physical examinations were consistent with an enlarging areolar breast mass with skin ulcerations and nipple retraction. The right breast was moderately tender on palpation. Due to the discordance between the pathology report and physical examination, a repeat ultrasound-guided biopsy was recommended for further management. No medications were prescribed to the patient, and conservative measures were taken because the final diagnosis was not confirmed. Upon repeat biopsy, physical examination revealed that the large right breast mass had decreased in size significantly. The decreasing size of the lesion (mass effect), decreasing size of the lymph node, and the nature of the ulcer now healing ruled out inflammatory breast cancer, and the physician suspected an idiopathic aetiology, instead of an inflammatory or infectious cause of this patient's presentation. A multidisciplinary approach was established for the patient, with a primary care physician and surgeon for further management if there were signs of disease progression. Discussion 'This case illustrates the diagnostic challenges of inflammatory breast lesions with overlapping clinical presentations. While initial findings suggested inflammatory breast cancer, biopsy results were negative for malignancy, pointing towards a benign inflammatory or infectious aetiology, such as idiopathic granulomatous mastitis or cat scratch disease. The spontaneous improvement after conservative management provided further evidence against a malignant process. This case reinforces the need for interdisciplinary collaboration, and further research into inflammatory breast pathologies is vital. Maintaining an open perspective and integrating all available data are essential when evaluating breast masses, facilitating timely diagnosis, and preventing unnecessary aggressive treatments. This case concluded without a definitive diagnosis, highlighting the importance of flexible management guided by clinical improvement in complex presentations,' the authors wrote.
Wall Street Journal
12 minutes ago
- Wall Street Journal
Stellantis Takes $350 Million Hit From Tariffs
Stellantis's STLA -2.23%decrease; red down pointing triangle earnings took a hit of around $350 million from U.S. tariffs, while restructuring efforts and higher costs also dragged on the Jeep maker's results. The carmaker on Monday said it swung to a net loss in the first half of the year, as it booked 300 million euros ($348.8 million) of net costs from the early effects of the tariffs that include the loss of planned production.
